Go Pro
→ This AI Stock Reminds One Analyst of Early Nvidia (From Brownstone Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
$23.49
+0.0%		$29.19
$21.80
▼
$39.71
$478.07M1.13372,144 shs221,117 shs
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
$13.42
+16.7%		$14.99
$8.60
▼
$17.78
$432.64M0.75562,205 shs1.60 million shs
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
$49.82
+0.2%		$69.77
$48.94
▼
$123.75
$484.08M-5.3690,027 shs79,318 shs
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
$0.60
-12.0%		$1.31
$0.59
▼
$3.65
$127.32M2.711.64 million shs2.28 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-0.55%-7.74%-31.08%-12.03%-4.67%
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
-9.66%-14.18%-32.55%-24.54%-2.71%
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
-3.72%-18.02%-31.69%-25.25%-13.42%
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
-2.05%-12.96%-51.25%-58.17%-61.50%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
$23.49
+0.0%		$29.19
$21.80
▼
$39.71
$478.07M1.13372,144 shs221,117 shs
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
$13.42
+16.7%		$14.99
$8.60
▼
$17.78
$432.64M0.75562,205 shs1.60 million shs
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
$49.82
+0.2%		$69.77
$48.94
▼
$123.75
$484.08M-5.3690,027 shs79,318 shs
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
$0.60
-12.0%		$1.31
$0.59
▼
$3.65
$127.32M2.711.64 million shs2.28 million shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-0.55%-7.74%-31.08%-12.03%-4.67%
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
-9.66%-14.18%-32.55%-24.54%-2.71%
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
-3.72%-18.02%-31.69%-25.25%-13.42%
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
-2.05%-12.96%-51.25%-58.17%-61.50%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
2.83
Moderate Buy$47.50102.21% Upside
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
2.50
Moderate Buy$22.1765.18% Upside
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
2.90
Moderate Buy$143.83188.71% Upside
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
2.78
Moderate Buy$6.571,002.22% Upside

Current Analyst Ratings Breakdown

Latest NMRA, DRUG, ASMB, and CTNM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/30/2026
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$28.00
9/28/2026
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetEqual Weight$18.00 ➝ $17.00
9/28/2026
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
Lifesci Capital logo
Lifesci Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
9/25/2026
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
9/15/2026
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
JonesTrading logo
JonesTrading
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$26.00 ➝ $24.00
9/15/2026
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$20.00 ➝ $19.00
9/15/2026
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
9/1/2026
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$53.00
9/1/2026
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$52.00
9/1/2026
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$52.00
9/1/2026
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$53.00 ➝ $45.00
(Data available from 9/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
$74.85M6.39N/AN/A$13.04 per share1.80
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
$50M10.10N/AN/A$6.99 per share1.92
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
N/AN/AN/AN/A$8.33 per shareN/A
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
N/AN/AN/AN/A$0.62 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-$6.12M$1.0223.03469.80N/A-0.06%-0.02%-0.02%11/9/2026 (Estimated)
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
-$59.98M-$1.73N/AN/AN/AN/A-24.73%-23.51%10/29/2026 (Estimated)
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
-$8.74M-$2.08N/AN/AN/AN/A-12.46%-12.30%N/A
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
-$236.93M-$1.23N/AN/AN/AN/A-242.28%-131.32%11/5/2026 (Estimated)

Latest NMRA, DRUG, ASMB, and CTNM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/17/2026Q3 2026
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
-$1.2230-$0.17+$1.0530-$0.17N/AN/A
8/14/2026Q2 2026
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
-$0.2401-$0.23+$0.0101-$0.23N/AN/A
8/13/2026Q2 2026
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
-$0.7242-$0.20+$0.5242-$0.20$8.60 million$13.37 million
7/30/2026Q2 2026
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
-$0.4488-$0.40+$0.0488-$0.40N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
N/AN/AN/AN/AN/A
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/AN/AN/AN/AN/A
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
N/AN/AN/AN/AN/A
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
N/A
13.99
13.99
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/A
37.17
37.17
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
N/A
122.00
122.00
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
1.19
4.50
4.50

Institutional Ownership

CompanyInstitutional Ownership
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
19.92%
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/A
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
40.52%
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
47.65%

Insider Ownership

CompanyInsider Ownership
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
3.50%
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
7.90%
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
42.66%
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
26.94%
CompanyEmployeesShares OutstandingFree FloatOptionable
Assembly Biosciences, Inc. stock logo
ASMB
Assembly Biosciences
7320.36 million19.65 millionOptionable
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
5137.62 million34.65 millionN/A
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
259.73 million5.58 millionNot Optionable
Neumora Therapeutics, Inc. stock logo
NMRA
Neumora Therapeutics
63187.90 million137.28 millionOptionable

Recent News About These Companies

Why Neumora Therapeutics, Inc.’s (NMRA) Stock Is Down 10.06%
September 30 at 7:37 PM  |  aaii.comA
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $6.57 Average Price Target from Analysts
September 24, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31043215
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Recommendation of "Moderate Buy" by Analysts
September 19, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-neumora-therapeutics-inc-nasdaq-nmra-given-average-recommendation-of-moderate-buy-by-analysts-2026-09-19/
Biotech Options Buzz: UTHR, NMRA, EWTX
September 18, 2026  |  schaeffersresearch.comhttps://www.schaeffersresearch.com/content/options/2026/09/18/biotech-options-buzz-uthr-nmra-ewtx
Neumora Therapeutics, Inc. (NMRA)
September 15, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/NMRA/latest-news/
BlackRock Inc. Buys Shares of 7,791,869 Neumora Therapeutics, Inc. $NMRA
September 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-blackrock-inc-buys-shares-of-7791869-neumora-therapeutics-inc-nmra-2026-09-04/
Top Neumora Executive Makes Notable Move With Insider Stock Sale
August 21, 2026  |  tipranks.comhttps://www.tipranks.com/news/insider-trading/top-neumora-executive-makes-notable-move-with-insider-stock-sale-insider-trading-news?utm_source=marketbeat.com&utm_medium=referral
Neumora Therapeutics Announces CEO Transition and Q2 Results
August 14, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/neumora-therapeutics-announces-ceo-transition-and-q2-results?utm_source=marketbeat.com&utm_medium=referral
Neumora Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/14/3345232/0/en/neumora-therapeutics-reports-second-quarter-2026-financial-results-and-provides-business-update.html
Neumora Therapeutics Shares Rise on Positive Obesity Drug Results
July 28, 2026  |  marketwatch.comhttps://www.marketwatch.com/story/neumora-therapeutics-shares-rise-on-positive-obesity-drug-results-e4d6ff10
Neumora advances NMRA-215 with positive toxicology results
July 27, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/neumora-advances-nmra-215-with-positive-toxicology-results?utm_source=marketbeat.com&utm_medium=referral
Neumora Therapeutics Reports Favorable Repeat Toxicology Results for NMRA-215 and Plans IND Submission in Q4 2026
July 27, 2026  |  quiverquant.comQ
Neumora Therapeutics Reports Favorable NMRA-215 Toxicology Results with Planned Clinical Advancement in 2026
July 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/27/3333375/0/en/neumora-therapeutics-reports-favorable-nmra-215-toxicology-results-with-planned-clinical-advancement-in-2026.html
Neumora Therapeutics (NMRA) Stock Sees Fair Value Falls After Navacaprant Discontinuation
July 11, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/neumora-therapeutics-nmra-stock-sees-150826430.html
Why Neumora Therapeutics, Inc. (NMRA) Is One of the Best Get Rich Quick Stocks to Buy
July 7, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/why-neumora-therapeutics-inc-nmra-055351885.html
Why Neumora Therapeutics, Inc.’s (NMRA) Stock Is Down 9.94%
June 18, 2026  |  aaii.comA
NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud
June 18, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260618422337/en/nmra-investor-alert-levi-korsinsky-investigates-neumora-therapeutics-nmra-for-potential-securities-fraud/
Why Neumora Therapeutics (NMRA) Faces a Major Catalyst From Navacaprant’s Upcoming Depression Data
June 17, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/why-neumora-therapeutics-nmra-faces-a-major-catalyst-from-navacaprants-upcoming-depression-data-1783033/
Three pivotal MDD trial failures for Neumora lead to staffing cuts
June 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/three-pivotal-mdd-trial-failures-155851143.html
Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA)
June 16, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/neumora-therapeutics-investigation-initiated-levi--korsinsky-investigates-the-officers-and-directors-of-neumora-therapeutics-nmra-302802184.html
Neumora Stock Plunges 49% After Late-Stage Depression Drug Failure
June 16, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2938022/neumora-stock-plunges-49-after-late-stage-depression-drug-failure?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2938022

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Scientist handles blood sample in lab, symbolizing early cancer detection.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
By Bridget Bennett | September 6, 2026
Revolution Medicines logo displayed over a laboratory background with a microscope, flasks, and test tubes.
Revolution Medicines Got Its Breakthrough—What Moves It Next?
By Chris Markoch | September 4, 2026
Eli Lilly logo displayed among medicine vials, pill bottles, blister packs, and injector pens on a table.
Lilly’s Merida Deal Shows the GLP-1 King Is Already Thinking Beyond Obesity
By Chris Markoch | September 2, 2026
Amgen logo displayed on a glass panel in a laboratory setting with microscopes and sample vials.
Amgen Drops 10% on a Trial It Didn't Even Run
By Chris Markoch | September 11, 2026
Three-panel composite showing a laboratory workbench, an open-plan office with desks, and a pharmacy with stocked medicine shelves.
3 Healthcare Stocks for 3 Stages of Life
By Jessica Mitacek | September 15, 2026
Assembly Biosciences stock logo

Assembly Biosciences NASDAQ:ASMB

$23.49 +0.01 (+0.04%)
Closing price 04:00 PM Eastern
Extended Trading
$23.50 +0.01 (+0.02%)
As of 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Contineum Therapeutics stock logo

Contineum Therapeutics NASDAQ:CTNM

$13.42 +1.92 (+16.70%)
Closing price 04:00 PM Eastern
Extended Trading
$13.82 +0.40 (+3.02%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Bright Minds Biosciences stock logo

Bright Minds Biosciences NASDAQ:DRUG

$49.82 +0.08 (+0.16%)
Closing price 04:00 PM Eastern
Extended Trading
$49.55 -0.27 (-0.54%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Neumora Therapeutics stock logo

Neumora Therapeutics NASDAQ:NMRA

$0.60 -0.08 (-12.01%)
Closing price 04:00 PM Eastern
Extended Trading
$0.60 +0.00 (+0.47%)
As of 07:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas